Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
BRISBANE, Calif., Oct. 31, 2016 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present how innovative pricing approaches, such as the company’s Responsible Pricing Model, can fortify existing incentives to bring therapies to the U.S. for neglected diseases during the Priority Review Voucher (PRV) Summit in Arlington, Va., November 2-3, 2016.
Dr. Durrant will also participate in a separate panel to discuss PRVs as a model to support the research and development of important medicines.
“The current PRV system is enlightened policy driving both immediate help, and future advancements, for neglected disease patients,” said Dr. Durrant. “We look forward to engaging in the conversation around serving the public health through these effective FDA incentives and responsible drug pricing.”
Details of the presentation and panel follow:
Title: Tackling Neglected Diseases through Responsible Pricing
Date: Wednesday, November 2, 2016
Time: 3:00 – 3:45 p.m. EDT
Presenter: Dr. Cameron Durrant, KaloBios Pharmaceuticals
Title: Panel: Priority Review Vouchers: A New Paradigm for Funding Research
Date: Wednesday, November 2, 2016
Time: 4:15 – 5:15 p.m. EDT
Participants: Xi Chen, PhD, Adena Partners Management; Dr. Cameron Durrant, KaloBios Pharmaceuticals; Charles Keller, MD, Children’s Cancer Therapy Development Institute; Curt H. LaBelle, MD, Global Health Investment Fund
For more information on the conference, please visit http://exlevents.com/priorityreviewvoucher/.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Kim Sutton Golodetz O: 212-838-3777 [email protected] Bruce Voss O: 310-691-7100 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
